▲ +67.07% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Brainsway in the last 3 months. The average price target is $13.75, with a high forecast of $15.00 and a low forecast of $12.00. The average price target represents a 67.07% upside from the last price of $8.23.
The current consensus among 4 contributing investment analysts is to buy stock in Brainsway.
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.